Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.71

Mkt cap

12M

Volume

54K

High

3.72

P/E Ratio

-0.08

52-wk high

20.83

Low

3.55

Div yield

N/A

52-wk low

1.80

Zacks Small-Cap Research has given Cingulate a $70 price valuation, indicating a positive outlook for the company's stock. This valuation suggests potential growth and investor interest in Cingulate.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 1:07 pm

Cingulate shares resumed trading after a circuit breaker halt, indicating significant volatility in the stock. Such halts are typically triggered by rapid price movements, suggesting heightened investor activity or news impacting the company.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 4:48 pm

Bit Digital shares rose 11% in pre-market trading due to better-than-expected Q2 sales and a new agreement with Boosteroid. The company reported a revenue of $29 million, surpassing estimates, despite missing EPS expectations. Other stocks like Treasure Global and Heramba Electric also saw significant pre-market gains.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 10:16 am

U.S. stocks rose with the Nasdaq gaining 150 points. ZIM Integrated Shipping Services reported strong Q2 results, boosting its stock. Alzamend Neuro surged 474% after announcing a partnership for a PTSD study. Sonder Holdings rose 98% following a licensing deal with Marriott and securing $146M in liquidity. Liquidia Corporation fell 29% after FDA's tentative approval of YUTREPIA. Theriva Biologics and Cingulate Inc. also saw significant declines.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 6:37 pm

Nikola Corporation's shares fell by 10.4% after announcing a securities purchase agreement and a mixed shelf offering. Other stocks like Alzamend Neuro and Virax Biolabs saw significant gains, while Liquidia Corporation and Theriva Biologics experienced notable declines.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 5:37 pm

U.S. stocks rose with the Dow Jones, NASDAQ, and S&P 500 all gaining. Alzamend Neuro shares surged 418% due to a new partnership for a PTSD treatment study. Virax Biolabs shares increased 308% following WHO's virus emergency declaration. Sonder Holdings shares rose 46% after a licensing agreement with Marriott. Liquidia Corporation shares fell 39% after FDA's tentative approval of YUTREPIA. Theriva Biologics shares dropped 29% following a reverse stock split. Cingulate shares decreased 33% after increasing its stock offering price.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 4:28 pm

Cingulate's stock is trading lower following the company's decision to increase the maximum offering price for its common stock from $8.47 million to $11.33 million.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:56 pm

Cingulate has increased the maximum offering price for its common stock under its sales agreement from $8.47 million to $11.33 million. The company filed a prospectus supplement for an additional $2.86 million of shares, having already sold shares worth $8.47 million.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:48 pm

Xperi Inc. (NYSE:XPER) shares rose 11.6% in pre-market trading after announcing an $80 million asset sale agreement with Amazon.com services. Other notable pre-market movers include Applied DNA Sciences, Inc. (NASDAQ:APDN) up 130%, GeoVax Labs, Inc. (NASDAQ:GOVX) up 56%, and fuboTV Inc. (NYSE:FUBO) up 8.5% following a legal win against major media companies.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 9:18 am

Cingulate Inc. (NASDAQ:CING) shares surged by 239% after the company was granted a European patent for its ADHD treatment, CTx-1301. This patent covers up to 30 European territories, including the UK. Cingulate is also preparing to file a New Drug Application with the U.S. FDA.

Portfolio Pulse from Vaishali Prayag

August 16, 2024 | 6:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.